Y-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025

Rhea-AI Summary

Y-mAbs Therapeutics (NASDAQ:YMAB), a commercial-stage biopharmaceutical company specializing in antibody-based cancer therapeutics, will release its Q2 2025 financial results on Friday, August 8, 2025, before market open.

Due to the previously announced transaction with SERB Pharmaceuticals affiliates, the company will not conduct an earnings conference call for this quarter.

PRINCETON, N.J., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the “Company” or “Y-mAbs”) (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the development and commercialization of antibody-based therapeutics for the treatment of cancer, today announced it will report results for the second quarter 2025 before the market open on Friday, August 8, 2025.

In light of the previously announced transaction with affiliated entities of SERB Pharmaceuticals, Y-mAbs will not be hosting an earnings conference call.

About Y-mAbs

Y-mAbs is a commercial-stage biopharmaceutical company focused on the development and commercialization of novel, radioimmunotherapy and antibody-based therapeutic cancer products. The Company’s broad and advanced commercial product pipeline includes the anti-GD2 therapy DANYELZA^® (naxitamab-gqgk), the first FDA-approved treatment for patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow after a partial response, minor response, or stable disease to prior therapy. The Company’s technologies include its investigational Self-Assembly DisAssembly (“SADA”) Pretargeted Radioimmunotherapy Platform (“PRIT”) and bispecific antibodies generated using the Y-BiClone platform.

SADA^®, SADA PRIT^™, DANYELZA^® and Y-mAbs^® are registered trademarks of Y-mAbs Therapeutics, Inc.

CONTACTS

Investor and Media Contacts:

Courtney Dugan
VP, Head of Investor Relations
cdu@ymabs.com

Aaron Palash / Fouad Boutros
Joele Frank, Wilkinson Brimmer Katcher
apalash@joelefrank.com
fboutros@joelefrank.com
212-355-4449

FAQ

When will Y-mAbs (NASDAQ:YMAB) release Q2 2025 earnings?

Y-mAbs will release Q2 2025 earnings before market open on Friday, August 8, 2025.

Why isn't Y-mAbs holding a Q2 2025 earnings conference call?

Y-mAbs will not host an earnings call due to the previously announced transaction with SERB Pharmaceuticals affiliates.

What is Y-mAbs Therapeutics' main business focus?

Y-mAbs is a commercial-stage biopharmaceutical company focused on developing and commercializing antibody-based therapeutics for cancer treatment.

Where can investors access Y-mAbs' Q2 2025 financial results?

Y-mAbs' Q2 2025 financial results will be available through their public financial releases before market open on August 8, 2025.